Aggressive corticotroph tumors and carcinomas

Area of Science:

• Endocrinology
• Oncology
• Neurosurgery

Background:

• Pituitary tumors are typically benign but aggressive variants and carcinomas present significant mortality and treatment challenges.
• Aggressive pituitary tumors and carcinomas are associated with a high mortality rate.
• Corticotroph tumors constitute nearly half of aggressive pituitary tumors, indicating a distinct prognosis.

Purpose of the Study:

• To review the clinical, pathological, and molecular features of aggressive corticotroph tumors and carcinomas.
• To describe the efficacy of current and emerging treatments for these rare and aggressive neoplasms.

Main Methods:

• Literature review of clinical studies, pathological findings, and molecular markers.
• Analysis of treatment outcomes for aggressive pituitary tumors, including temozolomide and immunotherapy.

Main Results:

• Limited prognostic markers exist for early management of aggressive pituitary tumors.
• Temozolomide is the first-line treatment for aggressive pituitary tumors and carcinomas.
• Immune checkpoint inhibitors represent a novel therapeutic option for treatment-resistant cases.

Conclusions:

• Aggressive corticotroph tumors and carcinomas require specialized diagnostic and therapeutic approaches.
• Further research into prognostic markers and novel treatments is crucial for improving patient outcomes.